Tenax Therapeutics
Chapel Hill · Founded 1967
About Tenax Therapeutics
Tenax Therapeutics is a pharmaceutical company that focuses on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. Tenax Therapeutics develops novel dosing and formulations of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension. Imatinib, which acts on underlying cellular proliferative pathways linked to PAH, has the potential to be the first disease-modifying therapy for the disease.
Company Facts
- Founded: 1967
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $233.3M
- Funding stage: IPO
- Last round: Post-IPO Equity (Mar 2025)
- Ticker: nasdaq:TENX
- Website: tenaxthera.com
- Phone: 9198552133
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/tenax-therapeutics-77236 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.